Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the name-brand medicine. The company says it trying to stop them.

Incyte Corp's new chief executive, Bill Meury, outlined a growth strategy on Tuesday focused on accelerating drug development and prudent capital allocation, as the company faces the looming patent ...

Chewy Inc. CHWY delivered a strong and well-rounded performance across all major segments in the first quarter of fiscal 2025. Net sales rose 8.3% year over year to $3.12 billion, exceeding the high ...

New Wegovy prescriptions have increased by about 33% since May 22, when a U.S. Food and Drug Administration ban on so-called ...

Chewy will not receive any proceeds from this offering. Meanwhile, JMP Securities and Citizens JMP have both raised their price targets for Chewy to $48, citing the company’s strong core business and ...

Investing.com - BofA Securities has reiterated its Buy rating and $49.00 price target on Chewy Inc . (NYSE: CHWY), citing the pet retailer’s growth potential in veterinary care and pharmaceuticals.